<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00796731</url>
  </required_header>
  <id_info>
    <org_study_id>TED6829</org_study_id>
    <secondary_id>EudraCT 2007-004868-41</secondary_id>
    <nct_id>NCT00796731</nct_id>
  </id_info>
  <brief_title>SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Dose-escalation, Safety and Pharmacokinetic Study of SAR3419 Administered as a Single Agent by Intravenous Infusion Once Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma (NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine the maximum tolerated dose (MTD) of SAR3419 according
      to the dose limiting toxicities (DLTs) observed when administered as a single agent once
      weekly.

      Secondary objectives are:

        -  to characterize the global safety profile

        -  to evaluate the pharmacokinetic (PK) profile of SAR3419 in the proposed dosing schedule

        -  to assess preliminary evidence of anti-lymphoma activity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of DLT(s) at each dose level</measure>
    <time_frame>during the initial 3-week period of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative DLT(s)</measure>
    <time_frame>over the entire period of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events and laboratory abnormalities</measure>
    <time_frame>study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response (complete response, partial response) and duration of the response</measure>
    <time_frame>study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameters</measure>
    <time_frame>Study period</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">77</enrollment>
  <condition>Lymphoma</condition>
  <condition>Non-Hodgkin</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR3419</intervention_name>
    <description>administered by intravenous infusion</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of B-cell non Hodgkin's lymphoma

          -  Relapsed or refractory after standard treatments and with no curative option with
             conventional therapy (Patients having undergone stem cell transplantation may be
             included)

          -  CD19 positive disease by flow cytometry or immunohistochemistry

        Exclusion Criteria:

          -  Burkitt's lymphoma, Lymphoblastic lymphoma, Chronic lymphocytic leukemia (Small
             lymphocytic lymphoma may be included)

          -  Evidence of cerebral or meningeal involvement by lymphoma

          -  Patients without bi-dimensionally measurable disease

          -  ECOG performance status &gt; 2

          -  Life expectancy less than 3 months

          -  Chemotherapy or radiation therapy or other investigational agents within 4 weeks prior
             to entering the study

          -  Previous radioimmunotherapy within 12 weeks

          -  Known anaphylaxis to infused proteins

          -  HIV, HBV and HCV positivity

          -  Poor kidney, liver and bone marrow functions

          -  Any serious active disease or co-morbid condition, which, in the opinion of the
             principle investigator, will interfere with the safety or the compliance with the
             study

          -  Pregnant or breast-feeding women

          -  Patients with reproductive potential without effective birth control methods

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertrand COIFFIER, Professor of Hematology</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Lyon Sud, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 250004</name>
      <address>
        <city>Creteil Cedex</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 250006</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 250001</name>
      <address>
        <city>Pierre Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 250005</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 250003</name>
      <address>
        <city>Rouen Cedex</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 250002</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2008</study_first_submitted>
  <study_first_submitted_qc>November 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2008</study_first_posted>
  <last_update_submitted>July 16, 2012</last_update_submitted>
  <last_update_submitted_qc>July 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-cell lymphoma</keyword>
  <keyword>NHL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

